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Introduction
The European Society of Gastrointestinal Endoscopy (ESGE) and
United European Gastroenterology (UEG) have identified quali-
ty of endoscopy as a major priority. The rationale for this prior-
ity and the methodology of the quality initiative process have
been described elsewhere [1]. The aim of the ESGE pancreato-
biliary endoscopy working group was to identify a list of key
performance measures for EUS and ERCP that would be univer-
sally applicable. As with previous ESGE performance measures
[2, 3] the focus was on metrics that met the following require-
ments: proven impact on clinically relevant outcomes or quality
of life; well-defined, and amenable to simple and robust meas-
urement; and applicability to all levels of endoscopy services.
This paper describes the methodological process utilized [1]
and reports the agreed list of key performance measures for
pancreatobiliary endoscopy.
Methodology
The multistep process of the methodology for developing per-
formance measures has been described previously [1]. During
initial meetings of the working group, a PICO approach (where
P stands for Population/Patient; I for Intervention/Indicator; C
for Comparator/Control; and O for Outcome) was used to de-
fine clinically relevant questions. Systematic literature searches
were then performed by an expert team of methodologists.
This in turn led to the development of performance measures
in a consensus process.
The PICOs and the clinical statements derived from these
were modified or excluded during iterative rounds of discussion
of the working group members during a Delphi process [4]
In total, working group members participated in two rounds
of voting to agree on performance measures in predefined do-
mains and on their respective thresholds, discussed below.
Statements were modified during the process and ultimately
discarded if agreement was not reached after two voting
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(EUS) and endoscopic retrograde cholangiopancreatogra-
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Europe adopt the following seven key and one minor per-
formance measures for EUS and ERCP, for measurement
and evaluation in daily practice at center and endoscopist
level:
1 Adequate antibiotic prophylaxis before ERCP (key per-
formance measure, at least 90%); 2 Antibiotic prophylaxis
before EUS-guided puncture of cystic lesions (key perform-
ance measure, at least 95%); 3 Bile duct cannulation rate
(key performance measure, at least 90%); 4 Tissue sam-
pling during EUS (key performance measure, at least 85%);
5 Appropriate stent placement in patients with biliary ob-
struction below the hilum (key performance measure, at
least 95%); 6 Bile duct stone extraction (key performance
measure, at least 90%); 7 Post-ERCP pancreatitis (key per-
formance measure, less than 10%). 8 Adequate documen-
tation of EUS landmarks (minor performance measure, at
least 90%).
This present list of quality performance measures for ERCP
and EUS recommended by ESGE should not be considered
to be exhaustive: it might be extended in future to address
further clinical and scientific issues.
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ABBREVIATIONS
ACG American College of Gastroenterology
ASGE American Society for Gastrointestinal Endos-
copy
CI confidence interval
ERCP endoscopic retrograde cholangiopancreato-
graphy
ESGE European Society of Gastrointestinal Endoscopy
EUS endoscopic ultrasound
EUS-FNA endoscopic ultrasound-guided fine needle
aspiration
FNB fine needle biopsy
GI gastrointestinal
GRADE Grading of Recommendations Assessment,
Development and Evaluation
ISFU Importance, Scientific acceptability, Feasibility,
Usability
N/A not available
NSAID nonsteroidal anti-inflammatory drug
PEP post-ERCP pancreatitis
PICO Population/Patient; Intervention/Indicator;
Comparator/Control; Outcome
PSC primary sclerosing cholangitis
PTCD percutaneous transhepatic choledochal
drainage
RCT randomized controlled trial
QIC Quality Improvement Committee
UEG United European Gastroenterology
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rounds. The agreement that is given for the different state-
ments refers to the last voting round in the Delphi process.
The threshold for agreement was set at 80% throughout the
process. The key performance measures were distinguished
from minor performance measures on the basis of the ISFU
criteria [1] (Importance, Scientific acceptability, Feasibility,
Usability, and comparison with competing measures), and
expressed by mean voting scores. We used the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) system to assess the quality of the available evidence
[5].
Performance measures for
pancreatobiliary endoscopy
Using the evidence derived by the literature search group and
input from the working group members, a total of 10 clinical
statements addressing 8 potential performance measures
grouped into five of the seven predefined quality domains
were formulated. Over the course of two voting rounds, a con-
sensus agreement was reached for 8 statements regarding 8
performance measures; 7 are considered to be key perform-
ance measures and one a minor performance measure. The de-
velopment process for performance measures can be reviewed
in the Supporting information (available online).
We used the highest mean voting scores to identify 7 key
performance measures for five of the seven quality domains
(▶Fig. 1). As mentioned above, the remaining performance
measure was considered to be a minor performance measure.
The pre-procedure domain and management of pathology do-
main each had 2 performance measures. All performance
measures were deemed valuable by the working group mem-
bers and were obtained after a rigorous process as described
above. The use of appropriate endoscopy reporting systems is
crucial for facilitating data retrieval on identified performance
measures [6].
All the performance measures are presented below, accord-
ing to domain, using the descriptive framework developed by
the quality improvement committee (QIC) and with a short
summary of evidence for the ISFU criteria. Each table describes
a performance measure, the level of agreement during the
modified Delphi process (scores), how the performance meas-
ure should be calculated, and recommendations supporting its
adoption. The tables also note the desired thresholds.
The minimum number needed to assess whether the
threshold for a certain performance measure has been
reached can be calculated by estimating the 95% confidence
intervals (CI) around the predefined threshold for different
sample sizes [3, 7]. As with previous ESGE performance meas-
ures, for issues of practicality and to simplify implementation
and auditing, we suggest that at least 100 consecutive pro-
cedures (or all of them if fewer than 100 procedures are
performed) should be measured to assess a performance
measure. Continuous monitoring is however the preferred
method of measurement.
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Pre-procedure
Adequate 
antibiotic 
prophylaxis 
before ERCP
(≥ 90 %)
Bile duct 
cannulation 
rate
(≥ 90 %)
Tissue 
sampling 
during 
EUS-FNA
(≥ 85 %)
Documentation
of EUS 
landmarks
(≥ 90 %)
Clearance of 
common bile
duct stones
(≥ 90 %)
Safety of ERCP
(PEP rate 
<10%)
Being covered
by Endoscopy 
Services 
Working 
Group
N/A
Adequate 
antibiotic 
prophylaxis 
before EUS
(≥ 95 %)
Stent 
placement in 
case of biliary 
obstruction
(≥ 95 %)
Completeness
of procedure
Identification
of pathology
Management
of pathology
Patient
experience
Post-procedureComplications
▶ Fig. 1 The domains and performance measures chosen by the pancreatobiliary working group. EUS-FNA, endoscopic ultrasound-fine needle
aspiration; ERCP, endoscopic retrograde cholangiopancreatography; PEP, post-ERCP pancreatitis; N/A, not available.
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1 Domain: Pre-procedure
The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ Routine antibiotic prophylaxis is not recommended for ERCP
in unselected patients. Antibiotic prophylaxis should be
given before ERCP for the subgroup of patients with pre-
dicted incomplete biliary drainage, e. g. those with primary
sclerosing cholangitis (PSC) and hilar tumors; to immuno-
compromised individuals and to patients with pancreatic
pseudocysts communicating with the pancreatic duct.
(Statement number 7.2)
Adherence to recommendations on prophylactic antibiotics be-
fore ERCP [8] should be monitored and reasons for deviation
documented. The indication for antibiotic prophylaxis should
be recorded in the endoscopy report.
Routine antibiotic prophylaxis is not recommended for ERCP
in unselected patients as prophylactic antibiotics do not signif-
icantly reduce cholangitis in this setting. A systematic review of
RCTs [9] reported that antibiotics did not significantly prevent
cholangitis in unselected patients.
A Cochrane systematic review of RCTs [10] concluded that
prophylactic antibiotics reduced cholangitis; however, in pa-
tients in whom biliary obstruction was relieved there was no
benefit in using prophylactic antibiotics.
The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ Prophylactic antibiotic administration should be performed
before EUS-guided puncture of cystic lesions in ≥95% of
cases. (Statement number 8.1)
The percentage of patients with administration of prophylactic
antibiotics before EUS-guided puncture of cystic lesions should
be at least 95% (minimum standard). In general, antibiotic pro-
phylaxis should be used; the reason for any deviation (patient
intolerance, patient preference etc.) should be reported.
The rate of infectious complications following EUS-guided
puncture of cystic lesions is low [11, 12]. There are no systema-
tic reviews or RCTs comparing antibiotics with no antibiotics
before EUS-guided puncture of cystic lesions although one
study compared two regimens of antibiotics [13], and two ret-
rospective cohort studies [14, 15] focused exclusively on pan-
creatic cystic lesions. The study by Kwok and colleagues [13],
in which 117 patients were screened over an 11-month period,
lacked statistical significance however, since only 22% of
screened patients could be enrolled. The observed rate of cyst
infection was zero. An adequately powered study to test non-
inferiority of withholding antibiotics in this setting would likely
Key performance
measure
Adequate antibiotic prophylaxis
before ERCP
Description The percentage of patients with adequate
administration of prophylactic antibiotics
before ERCP.
Domain Pre-procedure
Category Process
Rationale Reduction of infection, prevention of
inappropriate antibiotic use
Construct Denominator: Patients with indication
for antibiotic prophylaxis
Numerator: Patients receiving antibiotics
Exclusions: Patients who are on ongoing
antibiotic treatment
Calculation: Proportion (%)
Level of analysis: Service and endoscopist
level
Frequency: Yearly audit of a sample of
100 consecutive cases
Standards Minimum standard: 90%
Target standard: 95%
Consensus agreement
for performance
measure
100%
PICO number (see Sup-
porting information)
3.1
Evidence grading Low quality evidence
Key performance
measure
Antibiotic prophylaxis before
EUS-guided puncture of cystic lesions
Description The percentage of patients with prophy-
lactic antibiotics before EUS-guided
puncture of cystic lesions
Domain Pre-procedure
Category Process
Rationale Patient safety, reduction of infection
following EUS-fine needle aspiration
(EUS-FNA)
Construct Denominator: Patients undergoing EUS-
FNA in cystic lesions
Numerator: Patients in denominator
receiving antibiotics
Exclusions: Patients who are on ongoing
antibiotic treatment
Calculation: Proportion (%)
Level of analysis: Service and, if necessary,
endoscopist level
Frequency: Yearly, for a sample of 50 con-
secutive EUS-FNAs. If the minimum
standard is not reached, analysis on an
individual level should be performed.
Standards Minimum standard: 95%
Target standard: 95%
Consensus agreement
for performance
measure
90%
PICO number (see Sup-
porting information)
3.2
Evidence grading Very low quality of evidence
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be logistically challenging since the authors calculated that in-
clusion of between 614 and 2450 patients would be needed.
Current ESGE [16] and American Society for Gastrointestinal
Endoscopy (ASGE) [8] guidelines recommend the use of pro-
phylactic antibiotics for the EUS-guided puncture of cystic le-
sions although data are equivocal [14]. In addition, the use of
prophylactic antibiotics might not be free of adverse events.
2 Domain: Completeness of procedure
The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ In patients with normal anatomy and native papilla, bile duct
cannulation should be achieved in at least 90% of cases using
all available techniques. (Statement number 1.1)
Technical success at biliary ERCP is predicated on successful
deep cannulation of the desired duct. Success or failure of can-
nulation should be documented in the post-procedure report
for all cases. In certain clinical scenarios, e. g. pyloric or duode-
nal stenosis and post-surgical altered anatomy, conventional
ERCP may be impossible and such cases are not included in
this performance measure. In addition, patients with prior
sphincterotomy should not be included in the calculation of
cannulation rate. There are a number of potential determinants
of successful cannulation of a native papilla, including endos-
copist experience and case mix. The literature predominantly
reports outcomes from academic centers, where case mix and
experience may differ from other settings. The included studies
reported cannulation rates from 70.5% to 100% [17–43] with a
median of 96% and mean of 91.4%. The consensus of the work-
ing party was that a competent ERCP practitioner should
achieve a cannulation rate in excess of 90% with a target stand-
ard of 95% at expert centers. ESGE guidance on different tech-
niques is available [44].
During the voting process (second voting round), members
of the pancreatobiliary working group discussed whether this
performance measure (bile duct cannulation rate) should be
extended and be adopted to both duct systems in the pancrea-
tobiliary system – the common bile duct and the pancreatic
duct – by stating “cannulation rate of desired duct.” However,
to our knowledge, there are no data which would support
adopting such a performance measure.
3 Domain: Identification of pathology
Key performance
measure
Bile duct cannulation rate
Description The percentage of successful bile duct
cannulations in patients with normal
anatomy (and native papilla)
Domain Completeness of procedure
Category Process
Rationale Successful biliary ERCP requires deep can-
nulation of the common bile duct via the
major duodenal papilla. A low bile duct
cannulation rate is associated with a delay
in definitive therapy and increased risk of
adverse events, and leads to increased
costs and inconvenience as the examina
tion has to be repeated or recourse made
to alternative therapeutic techniques
Construct Denominator: All procedures in patients
with normal anatomy
Numerator: Procedures that document
successful biliary cannulation (report and
fluoroscopy)
Exclusions: Procedures with no indication
for biliary cannulation. Previous biliary
sphincterotomy
Calculation: Proportion (%)
Level of analysis: Service and endoscopist
level
Frequency: Yearly audit of a sample of
100 consecutive cases
Successful bile duct cannulation, meaning
deep cannulation of the common bile duct
via the major duodenal papilla, should be
documented in a written report as well as
in fluoroscopy documentation
Standards Minimum standard: 90%
Target standard: 95% (in expert centers)
Consensus agreement
for performance
measure
100%
PICO number (see Sup-
porting Information)
1.17
Evidence grading Low quality evidence
Key performance
measure
Tissue sampling during EUS
Description Frequency of obtaining a diagnostic tissue
sample in EUS-FNA or EUS-fine needle
biopsy (FNB) of solid lesions
Domain Procedure
Category Process
Rationale Improve technical success of EUS-FNA/FNB
of solid lesions
Construct Denominator: All EUS-FNAs of solid
lesions performed
Numerator: Successful acquisition of
diagnostic tissue of solid lesions during
EUS
Exclusions: Patients with post-surgery
altered anatomy
Calculation: Proportion (%)
Level of analysis: Service and endoscopist
level
Frequency: Yearly, for a sample of 50 con-
secutive EUS-FNAs. If the minimum stand-
ard is not reached, analysis on an individual
level should be performed
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The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ In patients with solid lesions undergoing EUS-FNA, the fre-
quency of obtaining a full diagnostic tissue sample should be
≥85%. (Statement number 5.1)
The percentage of patients in which a full diagnostic tissue
sample, meaning a tissue sample allowing an accurate diagno-
sis, is obtained in EUS-FNA of solid lesions should be documen-
ted. The frequency of successful EUS-FNA of a solid lesion
should be at least 85% (minimum standard); ESGE proposes a
target standard of 90%.
Since the evidence is of very low quality, this recommenda-
tion is to be considered as expert opinion. Although the evi-
dence is scarce as regards the available literature [45–56], we
consider the clinical issue of successful tissue sampling to be a
major element in EUS. Based on the impact of EUS-fine needle
puncture, whether performed as aspiration (FNA) or biopsy
(FNB), we feel that this clinical quality indicator must be used
as a key performance measure.
The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ Appropriate landmarks should be documented in ≥90% of
cases in patients undergoing EUS. (Statement 6.1)
The components of a complete EUS investigation will vary de-
pending on the indications for the procedure. In many cases,
however, the visualization and documentation of standardized
landmarks give a measure of the quality of the procedure. Doc-
umentation of the appropriate landmarks includes detailed de-
scription in the patient record of the endosonographic findings
of the EUS procedure, and ideally, procedure quality will be en-
hanced by image documentation of normal or diseased land-
marks. Such reporting forms the basis of the quality indicator.
Although EUS is not indicated for staging of metastatic tumors,
which might have been previously documented by other ima-
ging modalities, there are clinical settings in which EUS may be
indicated nevertheless, for example if therapeutic decision
making is based on EUS findings, or if EUS-FNA is used to obtain
a full diagnostic tissue sample (see domain above, Identifica-
tion of pathology) which may change the further management
of the patient.
There are few data supporting the specification of the land-
marks required for a high quality report, but the selection of
landmarks surely relates to the indication for the procedure.
The QIC working group agreed that, depending on the indica-
tion for EUS, the landmarks shown in ▶Table 1 should be eval-
uated during the EUS procedure and the assessment recorded
afterwards. This includes a written report and documentation
of the relevant images.
In 2015, an ASGE–American College of Gastroenterology
(ACG) task force published a work on quality indicators for EUS
[58]. The authors stated that inclusion of the indication for EUS
in the procedural documentation for all cases is a useful quality
measure for two reasons. First, it may provide a justification for
the procedure, serving as a means of tracking compliance with
accepted indications. Second, the indication puts the procedure
report into a context wherein reporting of certain EUS land-
marks and finding characteristics should logically follow. For ex-
ample, a detailed description of the pancreatobiliary system
may not be necessary when the indication for EUS is staging of
esophageal cancer. If the indication for the EUS examination is
Key performance
measure
Tissue sampling during EUS
Standards Minimum standard: 85%
Target standard: 90%
Consensus agreement
for performance
measure
90%
PICO number (see Sup-
porting Information)
1.21
Evidence grading Very low quality of evidence
Minor performance
measure
Adequate documentation of EUS
landmarks
Description Percentage of EUS reports that contain
appropriate documentation of relevant
landmarks
Domain Identification of pathology
Category Process
Rationale Ensure comprehensive identification of
pathology
Construct Denominator: All EUS procedures
Numerator: EUS procedures where the
landmark documentation is adequate
Exclusions: EUS-guided therapy. Sampling
of well-defined lesions where further ana-
tomical overview is irrelevant
Calculation: Proportion (%)
Level of analysis: Service and, if necessary,
individual
Frequency: Yearly, for a sample of 50 con-
secutive EUS procedures. If the minimum
standard is not reached, analysis on an
individual level should be performed
Minor performance
measure
Adequate documentation of EUS
landmarks
Standards Minimum standard: 90%
Target standard: 90%
Consensus agreement
for performance
measure
100%
PICO numbers (see
Supporting Informa-
tion)
2.1–2.4
Evidence grading Very low quality of evidence (expert
opinion)
Domagk Dirk et al. Performance measures for ERCP and EUS… Endoscopy 2018; 50: 1116–1127 1121
D
ow
nl
oa
de
d 
by
: S
ze
ge
d 
Un
ive
rs
ity
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
staging of esophageal cancer, certain landmarks should be
included (uT-stage and uN-stage, including celiac axis visuali-
zation). The exception to this is in the case of failed passage of a
stenosed stricture when the tumor cannot be safely passed.
4 Domain: Management of pathology
The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ After successful cannulation, stent placement should be
achieved in≥95% of cases in patients with biliary obstruction
below the hilum. (Statement number 3.1)
This statement refers to placement of plastic or metal stents.
Subhilar strictures are the type most commonly encountered
in daily practice. Stent placement in patients with obstruction
below the hilum is technically less challenging than placement
for obstruction at or above the hilum, with high success rates
reported [59, 60].
Indications include failure to clear bile duct stones, and the
presence of biliary strictures of benign or malignant origin.
Competent ERCP practitioners should achieve successful sub-
hilar stent placement in at least 95% of cases.
▶Table 1 Landmarks to be assessed at endoscopic ultrasound (EUS)
according to the indication for the procedure.
Indication for EUS Relevant landmarks for visualization
and documentation
Mediastinal lesion/
Esophageal cancer
Mass/tumor
Mediastinum (lymph nodes)
Gastroesophageal junction
Celiac axis (lymph nodes)
Left lobe of the liver (to rule out metastatic
disease)
Subepithelial tumor Subepithelial mass including the affected
wall layers
Regional lymph nodes
Vascular infiltration
Infiltration of surrounding organs (e. g. liver,
pancreas)
Pancreatobiliary
cancer
Entire pancreas including pancreatic mass
(tumor, cancer)
Biliary tract (common bile duct, cystic duct,
gallbladder)
Local lymph nodes (peripancreatic)
Celiac axis (lymph nodes)
Left lobe of the liver and visible parts of the
right lobe (to rule out metastatic disease)
Vascular infiltration: superior mesenteric ar-
tery, superior mesenteric vein, portal vein
Infiltration of other peripancreatic organs
Rectal cancer Tumor including its location, expansion,
infiltration of surrounding structures
Surrounding structures: genitourinary
structures, iliac vessels, sphincter apparatus,
lymph nodes
Key performance
measure
Appropriate stent placement in patients
with biliary obstruction below the
hilum
Description Percentage of successful stent placements
in cases of strictures located below the
liver hilum, after successful cannulation
Domain Completeness of procedure
Category Process
Rationale Unsuccessful stent placement is associated
with an increased risk of cholangitis and
entails further health care costs and poten-
tial hospitalization.
Key performance
measure
Appropriate stent placement in patients
with biliary obstruction below the
hilum
Construct Denominator: All ERCPs in patients with
subhilar biliary strictures requiring stent
placement, after successful cannulation
Numerator: Successful stent placement
Calculation: Proportion (%)
Level of analysis: Service and endoscopist
level
Frequency: Yearly audit
Standards Minimum standard: 95%
Target standard: 95%
Consensus agreement
for performance meas-
ure
90%
PICO number (see Sup-
porting Information)
1.19
Evidence grading Low quality evidence
Key performance
measure
Bile duct stone extraction
Description Adequate removal of bile duct stones
(< 10mm) utilizing a retrieval balloon or
basket
Domain Management of pathology
Category Process
Rationale Incomplete stone extraction increases the
risk of cholangitis and entails further
health care costs and potential hospitali-
zation.
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The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ After successful cannulation, clearance of bile duct stones
< 10mm should be achieved in at least 90% of cases.
(Statement number 2.1)
The endoscopy report should provide details about size, num-
ber, and position of stones in the bile duct, and whether they
were successfully cleared from the duct. All relevant findings,
such as the presence of a stricture, should also be recorded.
A range of techniques and devices, including balloon/basket
extraction, balloon dilation of the ampulla, and mechanical
lithotripsy, are available for clearance of stones from the bile
duct with high success rates reported for stones smaller than
10mm in size [61, 62]. Competent ERCP practitioners should
be able to achieve a duct clearance rate in excess of 90%.
5 Domain: Adverse events and harms
The acceptance of this performance measure is based on agree-
ment with the following statement:
▪ The rate of post-ERCP pancreatitis should be less than 10%.
(Statement number 4.1)
Post-ERCP pancreatitis (PEP) is the most common adverse event
following ERCP and is therefore the most appropriate indicator
of adverse event rate. There are a number of well-recognized
risk factors, including female sex, normal bilirubin, and pre-
vious PEP. A recent systematic review of randomized controlled
trials documented an overall PEP rate of 9.7% with a rate of
14.7% in high risk patients [64]. Large observational studies
have reported rates of between 2.7% and 5.1% [65–68]. A
minimum standard of < 10% adverse event rate (pancreatitis)
is therefore recommended, with a target standard of 5%. At
audit, the rate of pancreatitis should be evaluated in terms of
case mix. ESGE recommends PEP prophylaxis using rectal non-
steroidal anti-inflammatory drug (NSAID) administration for all
patients in whom a contraindication does not exist, and consid-
eration of placement of pancreatic duct stents in high risk cases
[69]. The working group suggests the documentation of use of
rectal NSAIDs and prophylactic pancreatic duct stenting, to
facilitate root cause analysis in severe cases of pancreatitis and
to investigate reasons why this performance measure might not
be reached.
Key performance
measure
Bile duct stone extraction
Construct Denominator: All ERCPs for patients with
bile duct stones of < 10mm in diameter
(after successful cannulation of the com-
mon bile duct)
Numerator: Successful stones removal
Calculation: Proportion (%)
Level of analysis: Service and endoscopist
level
Frequency: Yearly audit of a sample of
100 consecutive cases
Standards Minimum standard: 90%
Target standard: 95% (in expert centers)
Consensus agreement
for performance meas-
ure
90%
PICO number (see Sup-
porting Information)
1.18
Evidence grading Low quality evidence
Key performance
measure
Post-ERCP pancreatitis (PEP)
Description Rate of PEP diagnosed according to
consensus definition [63]
Domain Procedure
Category Process
Rationale Pancreatitis is the most frequent compli-
cation of ERCP and potentially life-
threatening. The rate of PEP is a surrogate
quality indicator for performance of ERCP
Key performance
measure
Post-ERCP pancreatitis (PEP)
Construct Denominator: All procedures
Numerator: Cases in which acute
pancreatitis develops
Exclusions: Patients with post-surgical
altered anatomy
Calculation: Proportion (%)
Level of analysis: Service and endoscopist
level
Frequency: Yearly audit of a sample of
100 consecutive cases. Rate of pancreatitis
should be evaluated according to the case
mix
Standards Minimum standard: < 10%
Target standard: < 5%
Consensus agreement
for performance
measure
100%
PICO number (see Sup-
porting Information)
1.7
Evidence grading Low quality evidence
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General conclusions, research priorities,
and future prospects
These performance measures, generated by evidence-based
consensus, can be used for pancreatobiliary endoscopy, includ-
ing ERCP and EUS (in general, as applied for large parts of the GI
tract). We used a systematic and scientifically based methodol-
ogy to substantiate the proposed measures with available evi-
dence where possible. As this is a largely unexplored field,
most of the evidence found was, as expected, graded as low
quality. This generated important research priorities, primarily
to audit the proposed performance measures and to evaluate
whether they do in fact influence health outcome. Service pro-
viders would then be responsive to the findings and change
practice. Furthermore, the working group identified several ad-
ditional research priorities; these are listed in ▶Table 2 (ERCP)
and ▶Table 3 (EUS) and will be addressed in a paper from the
ESGE Research Committee.
This manuscript, like the other ESGE quality improvement
papers, is a working document that will be used, it is hoped,
by national member societies to determine which performance
measures can feasibly be monitored in the setting of their
countries and which measures are relevant. The first task now
is to implement these new performance measures into endos-
copy practice throughout Europe on a national basis. This is in
order to determine the value of setting performance measures,
to allow audit against such measures, and, in the light of audit
findings, to permit responsive adaptation of performance
measures in the future.
The implementation of performance measures is important
to identify services and individual endoscopists with lower per-
formance levels. Obviously, there are no legal implications
associated with the ESGE QIC Initiative since these documents
are not guidelines but are rather guidance on how quality can
be monitored for all aspects of GI endoscopy.
The aim of setting performance measures is to improve the
quality of endoscopy, and we encourage individual endos-
copists, as well as heads of endoscopy units, to implement
these performance measures without delay. Since the tech-
niques of ERCP and EUS, belong to the most sophisticated
endoscopic examinations, with a flat learning curve, perform-
ance measures should be put in place as soon as possible to
monitor endoscopist and endoscopy unit performance. At a
unit level, this may mean investing in hardware to accommo-
date a more efficient auditing process.
Through such feedback, measures can be taken to improve
quality, to rise above the proposed minimum thresholds. This
should not be considered as a “1984”-like scenario with the
goal of penalizing specific endoscopists, but rather as a tool to
improve patient outcomes, and provide training and assistance
to endoscopists where needed. A second barrier may be the
perceived financial implications of establishing a quality control
system. The aim is to encourage hospital management to sup-
port the implementation of these performance measures in
endoscopy services. We think that in an era where hospital
accreditation is becoming more important, hospital adminis-
trations will be more inclined to support such actions.
Moreover, we owe it to our patients to overcome individual
or financial barriers to ensure that endoscopy services are of
the highest quality, and to set research priorities to gather
data that will inform the next generation of performance meas-
ures (▶Table4).
▶Table 2 Research priorities identified by the pancreatobiliary
working group for quality improvement performance measures:
endoscopic retrograde cholangiopancreatography (ERCP).
Prophylaxis of post-ERCP pancreatitis: Value of pancreatic duct stenting
vs. NSAIDs?
Where and when (early/late) is precut indicated and safe?
How to manage benign pancreatic strictures?
Is ERCP-radiofrequency ablation (RFA) safe and effective for palliative
cancer treatment?
What is the optimal endoscopic approach to access the biliary tree in
in patients with altered anatomy?
▶Table 3 Research priorities identified by the pancreatobiliary
working group for quality improvement performance measures:
endoscopic ultrasonography (EUS).
What are the thresholds for accurate T and N staging of GI malignan-
cies?
How does the accurate description of landmarks influence quality of
EUS staging?
How can the results of EUS-fine needle aspiration (FNA) (tissue sam-
pling) and fine needle biopsy (FNB) be improved?
▪ Value of rapid on-site cytological evaluation (ROSE)
▪ Formal EUS-FNA teaching classes/curriculum
▪ Clinical cytology for endoscopists
Therapeutic EUS
▪ Management (ablation) of cystic neoplasias of the pancreas
▪ Endosonography-guided ablation therapy and implantation of
diagnostic material (fiducial placement)
▪ Interventional endosonographic drainage procedures (e. g., ran-
domized controlled trial on EUS-biliary drainage vs. percutaneous
transhepatic choledochal drainage [PTCD])
▪ Endosonography-guided therapy of acute cholecystitis
How do we improve noninvasive diagnostic methods (e. g. contrast-
enhanced EUS, 3D-reconstruction) for differential diagnosis of pancre-
atic cancer and non-neoplastic diseases?
What is the optimal endoscopic approach to access the biliary tree in
in patients with altered anatomy?
What are the roles of MRCP, ERCP, and EUS in purely diagnostic clinical
questions?
MRCP, magnetic resonance cholangiopancreatography.
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Supporting information
The detailed literature searches performed by an expert team
of methodologists, as well as evolution and adaptation of the
different PICOs and clinical statements during the Delphi vot-
ing process can be viewed in Supporting Information on the
ESGE website.
online content viewable at:
https://www.esge.com/performance-measures-for-ercp-and-
eus.html
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